Curtana Pharmaceuticals is developing highly targeted therapies for the treatment of brain cancer, including glioblastoma in adults and pediatric high grade glioma in children.
Patients typically are treated with surgery, radiation, and chemotherapy. Unfortunately, current treatments offer little hope of significantly prolonging a patient’s life.
Curtana is advancing a novel small molecule therapy, CT-179, which has been shown to significantly prolong survival in relevant animal models. The target is Olig2, a cancer stem cell-associated transcription factor that is critical for tumor initiation and growth. CT-179 will enter clinical development in early 2018.
Learn more at: www.curtanapharma.com
